Safety-modified episomal vectors for human gene therapy

Area of Science:

• Molecular Biology
• Gene Therapy
• Virology

Background:

• Gene therapy efficacy is often limited by viral and plasmid vector expression levels.
• Enhancing heterologous gene expression is crucial for effective gene therapy applications.

Purpose of the Study:

• To develop a safety-modified episomal expression vector for enhanced gene expression in human cells.
• To investigate the replication and expression capabilities of SV40-based episomes utilizing a novel T antigen mutant.

Main Methods:

• Development of an episomal vector system using a simian virus 40 (SV40) large T antigen mutant (107/402-T) deficient in binding tumor suppressors.
• Assessment of episomal replication in various human and animal cell lines.
• Evaluation of gene expression levels compared to standard plasmid constructs.
• In vivo studies using liposome/DNA complexes injected into tumor explants in nude mice.

Main Results:

• SV40-based episomes replicated to thousands of copies within 2-4 days in human cells.
• The 107/402-T mutant demonstrated enhanced replication compared to wild-type T antigen.
• Episomes encoding 107/402-T yielded 10- to 100-fold higher gene expression levels.
• Extrachromosomal replication of SV40-based episomes was confirmed in vivo in human cells within tumors.

Conclusions:

• Safety-modified SV40-based episomes efficiently replicate extrachromosomally in human cells.
• These episomes achieve significantly enhanced therapeutic gene expression.
• The developed vector system holds strong potential for effective cancer gene therapy.